Montara Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Montara Therapeutics, Inc. - overview
Established
2022
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2022 by CEO Nicholas T. Hertz, PhD, Montara Therapeutics, Inc. operates as a precision-medicine biotech company that focuses on creating CNS disease medications using precision pharmacology, human genomics, and machine learning to enhance drug safety and effectiveness in neurological disorders. In January 2024, Montara Therapeutics, Inc.
raised an amount of USD 8 million in venture funding from unspecified investors. The company provides treatments for patients with central nervous system (CNS) conditions.
Current Investors
SV Health Investors, Dolby Family Ventures, KdT Ventures
Primary Industry
Biotechnology
Sub Industries
Biotechnology, Pharmaceutical Research & Development
Website
www.montaratx.com
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.